Drug Profile

Zelquistinel - Gate Neurosciences

Alternative Names: AGN-241751; GATE-251

Latest Information Update: 03 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator
Developer AbbVie; Gate Neurosciences
Class Amines; Antidepressants; Antipsychotics; Aza compounds; Esters; Ketones; Small molecules; Spiro compounds
Mechanism of Action NMDA receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Major depressive disorder
Phase I Schizophrenia

Most Recent Events

20 Feb 2025 Gate Neurosciences plans a synaptic function biomarker study in Alzheimer disease
15 Jan 2025 Gate Neurosciences initiates a phase II trial for Major depressive disorder in US (PO) (NCT06547489)
24 Jul 2024 Phase-I clinical trials in Schizophrenia (PO) before July 2024 (Gate Neuroscinces pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com